Fredun Pharmaceuticals Limited has announced an investor meeting scheduled for March 18, 2026 in Mumbai, as part of its ongoing investor engagement activities. The company has formally notified BSE Limited about this meeting in compliance with regulatory requirements.

Meeting Details

The investor meeting has been organized with the following specifications:

Regulatory Compliance

The company has informed BSE Limited about this investor meeting pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official communication was dated March 16, 2026, providing advance notice of the scheduled meeting.

Management Participation

The meeting will involve the management of Fredun Pharmaceuticals Limited engaging with a group of investors. Managing Director Fredun Medhora, holding DIN 01745348, has signed the official communication to BSE Limited regarding this investor engagement activity.

Investor Engagement Focus

The meeting agenda centers on two primary areas:

• Business Overview: Discussion of the company's current business operations and strategic direction
• Financial Performance: Review of the company's financial metrics and performance indicators

This investor meeting represents part of Fredun Pharmaceuticals Limited's commitment to maintaining transparent communication with its investor community and ensuring regular engagement on business developments and financial progress.

Fredun Pharmaceuticals Limited has secured a significant credit rating upgrade from Infomerics Valuation and Rating Limited, marking a key milestone in the company's financial journey. The diversified pharmaceutical manufacturer, which operates across generics, cosmeceuticals, nutraceuticals, mobility and animal healthcare products, announced the upgrade on February 25, 2026.

Credit Rating Enhancement Details

Infomerics has upgraded the company's long-term bank facilities to IVR BBB+ with Stable Outlook from the previous IVR BBB with Stable Outlook rating. The rating agency simultaneously reaffirmed the short-term rating at IVR A2, demonstrating confidence in the company's near-term financial obligations management.

Performance Foundation for Upgrade

The rating upgrade reflects the company's strengthened operational performance and disciplined capital management demonstrated across FY24 and FY25. The upgraded IVR BBB+ rating indicates an enhanced degree of safety regarding timely servicing of financial obligations and demonstrates improving credit quality. The stable outlook signifies the rating agency's confidence in the company's ability to sustain its performance trajectory and maintain a balanced financial risk profile.

Notably, this follows a similar upgrade from Brickwork, which previously raised the company's bank facility credit rating from A3+ to A2, further validating the strengthening fundamentals.

Strategic Business Impact

This credit rating enhancement provides multiple strategic advantages for Fredun Pharmaceuticals as it continues expanding its global footprint. The upgrade strengthens banking confidence and institutional credibility while improving financial flexibility to support expansion initiatives. Additionally, it offers potential optimization of borrowing costs and enhanced positioning for future growth capital requirements.

As the company continues to expand its export presence across Africa, Southeast Asia, CIS countries and Latin America, the upgraded credit rating strengthens its financial flexibility to efficiently manage working capital and support strategic growth initiatives.

Management Commentary and Outlook

Commenting on the development, Managing Director Fredun Medhora stated, "This upgrade is encouraging for all of us at Fredun. It reflects the hard work of our team and the disciplined manner in which we are building the business. As we continue to grow across markets, our focus remains on strengthening the Company's foundation while pursuing larger opportunities responsibly."

Company Financial Performance

Fredun Pharmaceuticals reported strong financial results in FY25, demonstrating the operational strength that supported the rating upgrade:

The company maintains a diverse product portfolio spanning antihypertensives, antidiabetic medications, antiretroviral drugs, narcotics, dietary supplements, nutraceuticals, cosmeceuticals, and animal healthcare products. Its primary export markets include Africa, Southeast Asia, Commonwealth of Independent States countries, and Latin America, positioning it as a globally competitive pharmaceutical platform.